Standout Papers

Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled,... 2011 2026 2016 2021 528
  1. Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial (2011)
    Ludwig Kappos, David Li et al. The Lancet

Immediate Impact

2 from Science/Nature 63 standout
Sub-graph 1 of 22

Citing Papers

Neutrophil Membrane‐Camouflaged Polyprodrug Nanomedicine for Inflammation Suppression in Ischemic Stroke Therapy
2024 Standout
Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies
2023 Standout
1 intermediate paper

Works of Robert Glanzman being referenced

EDSS variability before randomization may limit treatment discovery in primary progressive MS
2012

Author Peers

Author Last Decade Papers Cites
Robert Glanzman 342 512 153 288 14 1.0k
Suzanne Gazda 269 609 223 355 13 993
E. Verdun 426 820 256 144 24 1.1k
Volkmar Heidecke 281 372 107 58 42 1.3k
Niveditha Mohan 123 162 53 229 14 1.0k
Paul Kwon 53 111 50 264 18 899
J.C. Sipe 183 495 198 152 18 983
Sabine Bongardt 146 54 152 372 25 1.1k
R. Gilad 354 280 62 161 21 1.1k
Jana Lízrová Preiningerová 401 681 130 251 28 1.3k
Hannah Pellkofer 563 600 185 322 24 1.1k

All Works

Loading papers...

Rankless by CCL
2026